A TP receptor agonist
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

U-46619

Item No. 16450

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
(5Z)-7-[(1R,4S,5S,6R)-6-[(1E,3S)-3-hydroxy-1-octen-1-yl]-2-oxabicyclo[2.2.1]hept-5-yl]-5-heptenoic acid
CAS Number
56985-40-1
Synonyms
  • 9,11-dideoxy-9α,11α-methanoepoxy PGF2α
  • 9,11-dideoxy-9α,11α-methanoepoxy Prostaglandin F2α
Molecular Formula
C21H34O4
Formula Weight
350.5
Purity
≥98%
Formulation
A 10 mg/ml solution in methyl acetate
Solubility(Learn about Variance in Solubility)
DMF: 100 mg/mlDMSO: 100 mg/mlEthanol: 100 mg/mlPBS (pH 7.2): 1 mg/ml
SMILES
CCCCC[C@H](O)/C=C/[C@H]1C2OCC(C2)[C@@H]1C/C=C\CCCC(O)=O
InChi Code
InChI=1S/C21H34O4/c1-2-3-6-9-17(22)12-13-19-18(16-14-20(19)25-15-16)10-7-4-5-8-11-21(23)24/h4,7,12-13,16-20,22H,2-3,5-6,8-11,14-15H2,1H3,(H,23,24)/b7-4-,13-12+/t16?,17-,18-,19+,20?/m0/s1
InChi Key
LQANGKSBLPMBTJ-REGKDVDGSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $109

    Add

    5 mg

    $491

    Add

    10 mg

    $818

    Add
    Lipid Resource Center
    Discover Products & Resources for Lipid Research
    • High-purity lipid standards
    • Lipid roles in biology
    • Lipids in health & disease
    • Lipids for pharmaceutical development
    • Protocols, advice, & resources
    EXPLORE NOW
    Product Description

    U-46619 is a stable analog of the endoperoxide prostaglandin H2, and a TP receptor agonist.1 It exhibits properties similar to thromboxane A2, causing platelet shape change and aggregation, and contraction of vascular smooth muscle.2,3 Mean EC50 values for shape change in human, rat, and rabbit platelets are 4.8, 6.0, and 7.3 nM respectively, and for aggregation are 82, 145, and 65 nM, respectively.4

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Abramovitz, M., Adam, M., Boie, Y., et al. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim. Biophys. Acta 1483(2), 285-293 (2000).

    2. Coleman, R.A., Humphrey, P.P.A., Kennedy, I., et al. Comparison of the actions of U-46619, a prostaglandin H2-analogue, with those of prostaglandin H2 and thromboxane A2 on some isolated smooth muscle preparations. Br. J. Pharmacol. 73(3), 773-778 (1981).

    3. Liel, N., Mais, D.E., and Halushka, P.V. Binding of a thromboxane A2/prostaglandin H2 agonist [3H]U46619 to washed human platelets. Prostaglandins 33(6), 789-797 (1987).

    4. Tymkewycz, P.M., Jones, R.L., Wilson, N.H., et al. Heterogeneity of thromboxane A2 (TP-) receptors: Evidence from antagonist but not agonist potency measurements. Br. J. Pharmacol. 102(3), 607-614 (1991).

    Product Citations

    Yang, J., Yamashita-Kanemaru, Y., Morris, B.I., et al. Aspirin prevents metastasis by limiting platelet TXA2 suppression of T cell immunity. Nature (2025).

    Ray, J.W., Sun, X., Cruz-Diaz, N., et al. Sex differences in middle cerebral artery reactivity and hemodynamics independent from changes in systemic arterial stiffness in Sprague-Dawley rats. Physiol. Rep. 13(7), e70250 (2025).

    Shvetsova, A.A., Lazarenko, V.S., Gaynullina, D.K., et al. TWIK-related acid-sensitive potassium channels (TASK-1) emerge as contributors to tone regulation in renal arteries at alkaline pH. Front. Physiol. 13, 895863 (2022).

    Macáková, K., Řeháková, Z., Mladěnka, P., et al. In vitro platelet antiaggregatory properties of 4-methylcoumarins. Biochimie 94(12), 2681-2686 (2012).

    Pankey, E.A., Bhartiya, M., Badejo, A.M., Jr., et al. Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase activator, BAY 60-2770, are not dependent on endogenous nitric oxide or reduced heme. Am. J. Physiol. Heart Circ. Physiol. 300(3), H792-H802 (2011).

    Kogushi, M., Matsuoka, T., Kawata, T., et al. The novel and orally active thrombin receptor antagonist E5555 (Atopaxar) inhibits arterial thrombosis without affecting bleeding time in guinea pigs. Eur. J. Pharmacol. 657(1-3), 131-137 (2011).

    Zhang, D.-M., Lin, S.-M., Lau, C.-W., et al. Anemoside A3-induced relaxation in rat renal arteries: Role of endothelium and Ca2+ channel inhibition. Planta Med. 76(16), 1814-1819 (2010).

    Reese, J., O'Mara, P.W., Poole, S.D., et al. Regulation of the fetal mouse ductus arteriosus is dependent on interaction of nitric oxide and COX enzymes in the ductal wall. Prostaglandins Other Lipid Mediat. 88(3-4), 89-96 (2009).

    Yi, X.-Y., Gauthier, K.M., Cui, L., et al. Metabolism of adrenic acid to vasodilatory 1α,1β-dihomo-epoxyeicosatrienoic acids by bovine coronary arteries. Am. J. Physiol. Heart Circ. Physiol. 292(5), H2265-H2274 (2007).

    González-Luis, G., Pérez-Vizcaíno, F., García-Muñoz, F., et al. Age-related differences in vasoconstrictor responses to isoprostanes in piglet pulmonary and mesenteric vascular smooth muscle. Pediatr. Res. 57(6), 845-852 (2005).

    Opere, C.A., Zheng, W.D., Huang, J., et al. Dual effect of isoprostanes on the release of [3H]D-aspartate from isolated bovine retinae: Role of arachidonic acid metabolites. Neurochem. Res. 30(1), 129-137 (2005).

    Woodward, D.F., Krauss, A.H.P., Chen, J., et al. Pharmacological characterization of a novel antiglaucoma agent, bimatoprost (AGN 192024). J. Pharmacol. Exp. Ther. 305(2), 772-785 (2003).

    Yang, L., Yatomi, Y., Satoh, K., et al. Inhibitory effects of beraprost on platelet aggregation: Comparative study utilizing two methods of aggregometry. Thromb. Res. 94(1), 25-32 (1999).

    Bertolino, F., Valentin, J.P., Maffre, M., et al. Intrinsic activity of the non-prostanoid thromboxane A2 receptor antagonist, daltroban (BM 13,505), in human platelets in vitro and in the rat vasculature in vivo. Br. J. Pharmacol. 115, 210-216 (1995).